Extended Data Fig. 10: Erastin ameliorates corpse clearance in the wounds of db/db mice and promotes partial wound healing in GDF15 KO mice.
From: Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes
a, b, Erastin ameliorates corpse clearance with or without the addition of apoptotic bolus in in the wounds of db/db mice. Quantification of apoptotic cleaved caspase-3+ cells in wounded skin of a, normoglycemic (B6) mice at day 4 post-wounding and b, diabetic (db/db) mice at day 8 post-wounding treated with erastin or vehicle regimen versus erastin or DMSO (for vehicle control) without the single administration of the apoptotic bolus. (B6: n = 4; UNW; n = 10; Vehicle regimen; n = 11; Erastin regimen; n = 4; Vehicle or Erastin; db/db: n = 5 mice per group; * P < 0.05; ** P < 0.01 with unpaired, two-tailed t-test). c, Lysates were prepared using bone-marrow derived dendritic cells from WT, GDF15 KO and Slc7a11 KO mice, mRNA was isolated, followed by RT-qPCR analysis for Slc7a11. (n = 5 per genotype; data are presented as fold change to Slc7a11 expression to control (WT) BMDC). d, GDF15 deficiency does not impair DC efferocytosis. Kinetics of efferocytosis by GDF15 KO and WT BMDC. Live-cell imaging data are expressed as mean ± SEM with n = 12; WT, n = 8; GDF15KO. e, Erastin regimen promotes partial wound healing in GDF15 KO mice. Wound healing dynamics comparing GDF15 KO and littermate control mice treated with erastin or DMSO vehicle given on day 0 to day 2. All wound sizes are expressed as percentage of initial wound size at day 2 post-wounding. (n = 8; WT+Erastin, n = 9; WT+vehicle, KO+Vehicle, KO+Erastin; * P < 0.05; ** P < 0.01; between groups, via unpaired, two-tailed t-test. Violin plots (c), and the box and whiskers plots (a, b, e) show the minimum to maximum values with all independent replicates, center denotes median.
